Holen Sie sich die Stockscreener-App
1.55
2.65%
0.04
Schlusskurs vom Vortag:
$1.51
Offen:
$1.53
24-Stunden-Volumen:
20,279
Relative Volume:
0.08
Marktkapitalisierung:
$15.14M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.88M
KGV:
-2.0667
EPS:
-0.75
Netto-Cashflow:
$-25.20M
1W Leistung:
-9.88%
1M Leistung:
-35.42%
6M Leistung:
-31.42%
1J Leistung:
-81.00%
1-Tages-Spanne:
$1.51
$1.59
1-Wochen-Bereich:
$1.48
$1.7899
52-Wochen-Spanne:
$1.17
$8.685
In 8 Bio Inc Stock (INAB) Company Profile
Firmenname
In 8 Bio Inc
Sektor
Branche
Telefon
(646) 600-6438
Adresse
EMPIRE STATE BUILDING, NEW YORK
Compare INAB vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.55 | 14.75M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
487.43 | 122.19B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
772.19 | 83.21B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
840.28 | 51.13B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.85 | 43.68B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
369.00 | 41.01B | 4.98B | 69.60M | 525.67M | 0.5198 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-18 | Eingeleitet | Laidlaw | Buy |
| 2022-08-30 | Eingeleitet | H.C. Wainwright | Buy |
In 8 Bio Inc Aktie (INAB) Neueste Nachrichten
Gossamer Bio (GOSS) Downgraded by Wedbush with Significant PT Reduction | GOSS Stock News - GuruFocus
BioMarin’s top execs schedule four investor events in March - Stock Titan
Construction giant brings drug tests in-house with fingerprint scans at UK sites - Stock Titan
BIO-key to secure Mozambique digital payments for 36.6M people - Stock Titan
Axsome Therapeutics, Inc. SEC 10-K Report - TradingView
BioMarin (BMRN) grows 2025 revenue 13% and guides 2026 EPS to $4.95–$5.15 - Stock Titan
Inclement weather delays PROCEPT BioRobotics Q4 call, Investor Day - Stock Titan
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits
INmune Bio Inc. Announces Webinar on XPro1595 Registrational Pathway for Early Alzheimer's Disease Treatment - Quiver Quantitative
Alzheimer’s therapy XPro1595 nears key trial as INmune Bio details Phase 3 path - Stock Titan
Gossamer Bio reports PROSERA topline: missed primary 6MWD endpoint but secondary endpoints and high-risk subgroup favored seralutinib - TradingView
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension - Business Wire
INmune Bio to Host Feb. 26 Webinar Presenting MissionEB Phase III CORDStrom Data - TradingView
Biotech Passage Bio lines up Oppenheimer and TD Cowen investor talks - Stock Titan
Inmune Bio Inc Advances CORDStrom and XPro1595 Regulatory Pathways - TradingView
Annovis Bio, Inc. Secures DSMB Approval for Phase 3 Trial - TradingView
Upstream Bio posts mid-stage asthma trial win (UPB:NASDAQ) - Seeking Alpha
Upstream Bio, Inc. Reports Positive Phase 2 VALIANT Trial Results for Verekitug - TradingView
Severe asthma trial: experimental drug cuts attacks up to 56% - Stock Titan
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma - The Manila Times
What’s the outlook for Third Harmonic Bio Inc.’s sectorWeekly Trade Review & Entry Point Confirmation Alerts - mfd.ru
IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer - GlobeNewswire Inc.
Cabaletta Bio Takes Spotlight at Guggenheim Summit as Autoimmune Bet Advances - MyChesCo
KALA BIO (KALA) names director Avi Minkowitz CEO and CFO as David Lazar steps down - Stock Titan
Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewswire
Biotech Climb Bio to field questions at Guggenheim, Oppenheimer, Leerink events - stocktitan.net
GRI Bio Reiterates Full Year 2025 Financial Results, - GlobeNewswire
Entera Bio (NASDAQ: ENTX) widens OPKO partnership and appoints Steven Rubin to board - Stock Titan
KALA BIO Signs Securities Purchase Agreement With Series AAA Investors - TradingView
Tevogen Bio Holdings Inc Evaluates Special Cash Dividend - TradingView
What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now? - Yahoo Finance
GRI Bio (GRI) expands at-the-market equity program to $60M capacity - Stock Titan
Annovis Bio, Inc. Announces Progress in Alzheimer's and Parkinson's Trials - TradingView
GRI Bio, Inc. Announces Positive Phase 2a Clinical Trial Data for GRI-0621 - TradingView
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives - TradingView
Alzheimer’s trial signal and rare skin disease cell therapy at INmune Bio - Stock Titan
Korro Bio, Inc. Unveils KRRO-121 as a Potential First-in-Class Treatment - TradingView
GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures - GlobeNewswire
BofA Securities initiates coverage on Belite Bio stock with Buy rating - Investing.com
Climb Bio, Inc. (NASDAQ:CLYM) Shares Could Be 45% Below Their Intrinsic Value Estimate - Yahoo Finance
CEO shake-up at Zura Bio (NASDAQ: ZURA) with new director added - Stock Titan
KALA Bio Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nuvation Bio Inc. (NYSE:NUVB) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
With 63% institutional ownership, Gossamer Bio, Inc. (NASDAQ:GOSS) is a favorite amongst the big guns - Yahoo Finance UK
GRI Bio (NASDAQ: GRI) plans 1-for-28 reverse stock split in January - stocktitan.net
GRI Bio slashes share count with 1-for-28 split to meet Nasdaq price rule - Stock Titan
Nuvation Bio Inc. (NUVB) Price Target Lowered as IBTROZI Sales Meet Expectations - Insider Monkey
Here’s What the Wall Street Thinks About Nuvation Bio Inc. (NUVB) - Insider Monkey
Here's What the Wall Street Thinks About Nuvation Bio Inc. (NUVB) - Finviz
Access Bio Inc To Acquire 57 Billion Won Worth Of Shares And Majority Stake In Rfbio Co Ltd - TradingView
Palisade Bio Announces Two Abstracts Selected for Poster - GlobeNewswire
Finanzdaten der In 8 Bio Inc-Aktie (INAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.20%
0.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):